Hartford Courant

Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...
Seeking Alpha

Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine

Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and ...

Target beefs up protein, supplement offerings, capitalizing on weight loss drug trend

Target has expanded its protein and supplement sections as GLP-1 drugs like Ozempic reshape shopping habits, driving demand ...

Weight-loss drugs fill a treatment gap for women with hormone disorder PCOS, doctors say

Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...

Lilly’s experimental shot reduces body weight by 23% in study

A next-generation obesity shot from Eli Lilly & Co. helped patients lose almost a quarter of their body weight, potentially making the experimental drug the most potent weight loss medicine yet.

Biotech boss urges pharma to move on from ‘weight-loss Olympics’

Pharma companies need to move beyond the “weight loss Olympics” and focus on more durable treatments with fewer side effects, ...
KVIA

Ozempic face: The cosmetic concerns of rapid weight loss

Northwell Health reports that "Ozempic face" describes the facial changes from rapid weight loss using Ozempic, highlighting ...